TNPH yields 19230.77% · ARCC yields 10.82%● Live data
📍 TNPH pulled ahead of the other in Year 1
Combined, TNPH + ARCC cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of TNPH + ARCC for your $10,000?
Tian'an Pharmaceutical Co., Ltd. develops, manufactures, and sells traditional Chinese herbal medicines, including pallets, hard capsules, and soft ointments for the treatment and prevention of diseases in China. It also engages in the research and development of biology goods and health care products. The company's pharmaceutical and nutraceutical products include Compound Ginseng capsule, a Chinese medicine preparation that is used to cure and treat prostate gland proliferation; Nizhuanle Yin granule, a Chinese medicine preparation that treats the decomposition or inflammation of the stomach's mucous membrane; and Tianan soft capsule, which is used to adjust high amounts of fat in the blood stream, improve blood vessel ventilation, and soften blood vessels. Its products also include Tianan Pain Relief Capsule, a Chinese medicine preparation, which is under development to cure pain in joints, headache, pain from muscle injury, cancer, and gynecological disorders, as well as general pain. Tian' An Pharmaceutical sells its products to independent distributors, who sell products to pharmacies and drugstores, and hospitals. The company was founded in 2003 and is based in Xi'an, China.
Full TNPH Calculator →Ares Capital Corporation is a business development company specializing in acquisition, recapitalization, mezzanine debt, restructurings, rescue financing, and leveraged buyout transactions of middle market companies. It also makes growth capital and general refinancing. It prefers to make investments in companies engaged in the basic and growth manufacturing, business services, consumer products, health care products and services, and information technology service sectors. The fund will also consider investments in industries such as restaurants, retail, oil and gas, and technology sectors. It focuses on investments in Northeast, Mid-Atlantic, Southeast and Southwest regions from its New York office, the Midwest region, from the Chicago office, and the Western region from the Los Angeles office. The fund typically invests between $20 million and $200 million and a maximum of $400 million in companies with an EBITDA between $10 million and $250 million. It makes debt investments between $10 million and $100 million The fund invests through revolvers, first lien loans, warrants, unitranche structures, second lien loans, mezzanine debt, private high yield, junior capital, subordinated debt, and non-control preferred and common equity. The fund also selectively considers third-party-led senior and subordinated debt financings and opportunistically considers the purchase of stressed and discounted debt positions. The fund prefers to be an agent and/or lead the transactions in which it invests. The fund also seeks board representation in its portfolio companies.
Full ARCC Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.